Core Viewpoint - The company has signed exclusive distribution agreements for "Huanghelou" and "Taishan" cigars, expanding its global market presence and aiming to cultivate the Chinese cigar brand internationally [1] Group 1: Agreements and Market Expansion - On September 2, 2025, the company signed an exclusive distribution agreement for "Huanghelou" cigars with Hubei Tobacco Industrial Co., Ltd. [1] - On September 4, 2025, the company signed an exclusive agency agreement for "Taishan" cigars with Shandong Tobacco Industrial Co., Ltd. [1] - The exclusive distribution scope for "Huanghelou" and "Taishan" cigars has been expanded from specific markets to a global market, excluding mainland China [1] Group 2: Strategic Importance - This move follows a previous agreement signed on July 23, 2025, with Sichuan Tobacco Industrial Co., Ltd. for the global distribution of "Great Wall" cigars, marking significant progress in the company's global market layout for Chinese cigars [1] - The board believes that these agreements align with the overall interests of the company and its shareholders, potentially broadening development space and creating new profit growth points [1]

Core Viewpoint - The company has signed exclusive distribution agreements for its cigar brands in the global market, aiming to enhance the development of Chinese cigar brands and expand its international sales platform [1] Group 1 - The company announced the signing of an exclusive distribution agreement for the "Huanghelou" cigar with Hubei Tobacco on September 2, 2025 [1] - An exclusive agency agreement for the "Taishan" cigar was signed with Shandong Tobacco on September 4, 2025 [1] - These agreements are part of the company's strategy to promote the global sales platform for Chinese cigars [1]

中煙國際（香港）有限公司 China Tobacco International (HK) Company Limited （ ） 於 香 港 註 冊 成 立 的 有 限 公 司 （股份代號：6055） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 與湖北中煙簽訂「黃鶴樓」雪茄全球市場獨家經銷協議 及與山東中煙簽訂「泰山」雪茄全球市場獨家代理協議 自願性公告 本公告乃由中煙國際（香港）有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願刊 發，旨在向本公司股東（「股東」）及潛在投資者告知本集團的最新業務發展。 茲提述本公司日期為2024年4月8日及2025年7月25日之公告（「該等公告」）。除另有注明外， 本公告所用詞彙與該等公告所界定者具有相同涵義。 本公司董事會（「董事會」）欣然宣佈，本公司在向新增區域出口捲煙框架協議基礎上，於 2025年9月2日與湖北中煙工業有限責任公司（「湖北中煙」）簽訂「黃鶴樓」雪茄全球市場獨 家經銷協議（「黃鶴樓雪 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [7] Core Views - The company achieved a robust revenue growth of HK$ 10.316 billion in 2025H1, representing an 18.5% year-on-year increase, with a net profit of HK$ 706 million, up 9.8% [1] - The company continues to focus on capital market operations and international business expansion, aiming to enhance profitability through supply chain resilience and optimized pricing strategies [5] - The company is expected to benefit from its unique position as a platform and industry integrator in the tobacco export market, with projected revenues of HK$ 14.7 billion, HK$ 15.9 billion, and HK$ 17.1 billion for 2025-2027, reflecting growth rates of 12%, 8%, and 8% respectively [6] Revenue Breakdown - The tobacco leaf import business generated HK$ 8.399 billion in revenue, a 23.5% increase, with a volume of 97,900 tons, up 2.5%. However, gross profit declined by 7.7% due to rising costs [2] - Tobacco leaf export revenue reached HK$ 1.156 billion, a 25.9% increase, with a volume of 38,500 tons, up 12.7%, and gross profit surged by 124.1% due to market expansion and pricing strategy optimization [2] - Cigarette export revenue was HK$ 552 million, a slight increase of 0.8%, with a volume of 1.019 billion sticks, down 7.9%. Gross profit increased by 16.8% due to enhanced self-operated channel development [3] Regional Performance - The company's Brazilian operations saw a significant decline, with tobacco leaf export revenue dropping to HK$ 195 million, down 50.3%, and volume decreasing by 34.8% due to adverse weather conditions affecting production [4] - New tobacco product exports also faced challenges, with revenue falling to HK$ 15 million, down 66.5%, and volume down 65.4%, primarily due to geopolitical conflicts and regulatory changes in target markets [4] Financial Forecast - The company is projected to achieve net profits of HK$ 944 million, HK$ 1.090 billion, and HK$ 1.224 billion for 2025-2027, with growth rates of 11%, 15%, and 12% respectively [6] - The expected P/E ratios for the same period are 31.11X, 26.95X, and 24.00X, reflecting the company's growth potential and market position [6]

Core Viewpoint - China Tobacco Hong Kong (06055) saw a significant stock price increase, reaching a historical high of 42.2 HKD, driven by strong interim performance and positive market sentiment [1] Financial Performance - The company reported a revenue of 10.316 billion HKD, representing a year-on-year increase of 18.52% [1] - Shareholder profit amounted to 706 million HKD, reflecting a year-on-year growth of 9.79% [1] - A mid-term dividend of 0.19 HKD per share has been proposed [1] Business Operations - The strong revenue performance is attributed to the excellent performance of the company's tobacco leaf import and export business, achieving both volume and price increases in the first half of the year [1] - The company holds a unique operational position with strong bargaining power in the tobacco industry, which is expected to support continued stable growth in its core tobacco leaf import and export business [1] Market Position - Huatai Securities highlighted the company's exclusive operational status, which is expected to benefit from ongoing overseas expansion and potential mergers and acquisitions by China Tobacco [1] - Tianfeng Securities noted that China Tobacco Hong Kong is the designated entity for international business expansion and related trade activities, as per Document No. 60 from China Tobacco Corporation [1]

Core Viewpoint - China Tobacco Hong Kong (06055) has seen a significant stock price increase, reaching a historical high of 42.2 HKD, driven by strong mid-term performance and positive market sentiment [1] Financial Performance - The company reported a revenue of 10.316 billion HKD, representing a year-on-year increase of 18.52% [1] - Shareholder profit attributable to the company was 706 million HKD, up 9.79% year-on-year [1] - A mid-term dividend of 0.19 HKD per share has been proposed [1] Business Operations - The strong revenue performance is attributed to the excellent performance of the company's tobacco leaf import and export business, achieving both volume and price increases in the first half of the year [1] - Huatai Securities highlights the company's strong market position and pricing power, suggesting that the tobacco leaf import and export business is expected to continue steady growth [1] - Tianfeng Securities notes that China Tobacco Hong Kong holds exclusive operational rights for international tobacco business, as designated by the China National Tobacco Corporation [1] Future Outlook - The company's unique operational status is considered rare, and it is expected to benefit from ongoing overseas expansion and potential mergers and acquisitions by China Tobacco [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中煙國際（香港）有限公司 | | | 呈交日期: | 2025年9月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06055 | | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 691,680,000 | | 0 | | 691,680,000 | | 增加 / 減少 ( ...

Core Viewpoint - The company reported strong revenue growth and stable profits for the first half of 2025, driven by the import and export of tobacco leaf products, as well as cigarette exports, while increasing shareholder returns through dividends [1][2][4]. Revenue Summary - The company achieved a revenue of HKD 10.32 billion, representing an 18.5% increase year-on-year [1]. - Tobacco leaf imports generated revenue of HKD 8.40 billion, up 23.5%, with an import volume of 97,900 tons, a 2.5% increase, and an average import price of HKD 8.58 million per ton, up 20.5% [1]. - Tobacco leaf exports saw revenue of HKD 1.16 billion, a 25.9% increase, with an export volume of 38,500 tons, up 12.7%, and an average export price of HKD 30,000 per ton, up 11.7% [2]. - Cigarette exports generated revenue of HKD 550 million, a slight increase of 0.8%, with an export volume of 1.019 billion sticks, down 7.9%, and an average export price of HKD 0.54 per stick, up 9.4% [2]. Profitability Summary - The net profit for the first half of 2025 was HKD 706 million, reflecting a 9.8% increase, with a gross margin of 9.2%, down 1.9 percentage points [1]. - The gross margin for tobacco leaf imports was 8.2%, down 2.8 percentage points, primarily due to increased costs from CBT-sourced tobacco exceeding sales price increases [1]. - The gross margin for tobacco leaf exports improved to 5.5%, up 2.4 percentage points, due to enhanced pricing strategies and market expansion efforts [2]. - The gross margin for cigarette exports increased to 25.7%, up 3.5 percentage points, despite a decline in export volume [2]. Dividend and Future Outlook - The company proposed an interim dividend of HKD 0.19 per share, representing a 27% increase [1]. - The profit forecast for 2025-2027 has been raised, with expected net profits of HKD 940 million, HKD 1.04 billion, and HKD 1.18 billion, reflecting year-on-year growth of 9.6%, 11.4%, and 12.9% respectively [4]. - The diluted EPS is projected to be HKD 1.35, HKD 1.51, and HKD 1.70 for the years 2025, 2026, and 2027, with corresponding PE ratios of 27, 25, and 22 [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 中煙國際（香港）有限公司 China Tobacco International (HK) Company Limited （ 於 香 港 註 冊 成 立 的 有 限 公 司 ） （股份代號：6055） 持續關連交易 釐定年度上限 境外銷售煙葉類產品框架協議 於2025年8月29日，本公司與相關買方訂立境外銷售煙葉類產品框架協議，內容有關本 集團向中國煙草總公司旗下相關境外實體銷售煙葉類產品，作為煙葉類產品出口業務 的一部分。 各買方均為中國煙草總公司的附屬公司或聯營公司。中國煙草總公司通過其直接全資 附屬公司中煙國際集團，於本公告日期持有本公司已發行股本總額約72.29%，並為本公 司的最終控股股東。因此，各買方因屬中國煙草總公司的聯繫人，根據上市規則定義， 均為本公司的關連人士。 由於根據上市規則計算的適用百分比率，就境外銷售煙葉類產品框架協議項下擬進行 的銷售交易之最高年度上限超過0.1%但均少於 ...

Core Insights - The global oral tobacco market is projected to reach $11.232 billion in 2024, reflecting a year-on-year growth of 57.57%, and is expected to grow to $25.148 billion by 2028, with a CAGR of 22.32% from 2024 to 2028 [1][2] - The North American and European markets are experiencing high growth rates, while the Asian and African markets are in early stages, indicating significant potential for rapid development in emerging markets [1][2] - The FDA's approval of flavored oral tobacco products is anticipated to act as a catalyst for market growth, potentially increasing the overall market ceiling [1][4] Market Overview - The retail market for oral tobacco is highly concentrated, with Philip Morris International, British American Tobacco, and Altria Group holding market shares of 41.1%, 24.6%, and 13.8% respectively, totaling 79.5% of the market [2] - In 2024, the North American oral tobacco market is expected to reach $8.775 billion, growing by 58.30% year-on-year, while the European market is projected to reach $2.415 billion, with a year-on-year growth of 56.12% [1][2] Company Performance - Philip Morris International's ZYN nicotine pouch sales are projected to be 644 million boxes in 2024, a year-on-year increase of 52.93%, with U.S. sales accounting for 581 million boxes, up 51.49% [2] - British American Tobacco's oral tobacco sales, including brands like Velo and Grizzly, are expected to reach 8.3 billion pouches in 2024, reflecting a year-on-year growth of 55%, with U.S. sales surging by 234% [2] Regulatory Developments - The FDA has authorized the sale of 20 ZYN nicotine pouch products, which are deemed to have lower harmful components compared to traditional cigarettes and most smokeless tobacco products, aligning with public health standards [4] - The approval of flavored products is expected to enhance market growth and expand the market's potential [4] Industry Opportunities - Jin Cheng Pharmaceutical is increasing its production capacity to 200 tons per year, focusing on high-purity nicotine for new tobacco products, which positions the company to benefit from the expanding oral tobacco market [5][6] - The company has received various certifications, including FDA PMTA approval, which enhances its competitive edge in the market [6] Investment Recommendations - Companies to watch in the oral tobacco supply chain include Jin Cheng Pharmaceutical (300233.SZ) and Run Du Co., Ltd. (002923.SZ) [7]